中国临床药理学杂志2018，Vol.34Issue(5)：518-520,527,4.DOI:10.13699/j.cnki.1001-6821.2018.05.009
西格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床研究
Clinical trial of sitagliptin combined with metformin in the treatment of patients with type 2 diabetes and nonalcoholic fatty liver
摘要
Abstract
Objective To evaluate the clinical effect of sitagliptin combined with mefformin in the treatment of patients of type 2 diabetes (T2DM) with nonalcoholic fatty liver disease (NAFLD).Methods Ninety-four patients with T2DM and NAFLD were randomly divided into control group and treatment group,with 47 cases in each group.Control group was treated with metformin 0.5 g,oral,bid.Treatment group was orally given sitagliptin 0.1 g on the basis of control group,qd.Both groups were treated for 4 months.The clinical efficacy,homeostasis model assessment of insulin resistance (HOMA-IR),islet β cell function (HOMA-β),blood glucose,liver function and adverse drug reactions in two group were compared in two groups.Results After treatment,the total effective rates in treatment group and control group were 82.98％ (39 cases/47 cases) and 61.70％ (29 cases /47 cases),with significant difference (P ＜ 0.05).HOMA-IR in treatment group and control group were 1.06 ±0.08 and 1.13 ±0.11,HOMA-β were 85.70 ± 10.07 and 65.83 ±7.20,fasting blood glucose(FPG) were (6.07 ± 0.76) and (6.66 ± 0.80) mmol · L-1,2 h postprandial blood glucose (2 h PG) were (8.63 ± 1.07) and (9.36 ± 1.40) mmol · L-1,glycosylated hemoglobin (HbA1 c) were (5.84 ± 0.69) ％ and (6.39 ± 0.77) ％,alanine aminotransferase (ALT) were (30.76 ± 3.77) and (38.37 ± 3.72) mmol · L-1,aspartate aminotransferase (AST) were (34.06 ± 4.04) and (40.20 ± 4.69)mmol · L-1,all with significant difference (all P ＜ 0.05).There were 2 cases of constipation,4 cases of abdominal pain,4 cases of upper sense in control group,with the incidence of 21.28％ (10 cases/47 cases).There were 3 cases of constipation,2 cases of abdominal pain,3 cases of upper sense intreatment group,with the incidence of 17.02％ (8 cases/47 cases),with no significant difference (P ＞ 0.05).Conclusion The clinical effect of sitagliptin combined with metformin is better than metformin alone,it can reduce HOMA-IR,improve level of HOMA-β.关键词
2型糖尿病伴非酒精性脂肪肝/西格列汀/二甲双胍/胰岛素抵抗/胰岛β细胞功能Key words
type 2 diabetes with non-alcoholic fatty liver disease/sitagliptin/metformin/insulin resistance/islet β cell function分类
医药卫生引用本文复制引用
李斐,曲震理..西格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床研究[J].中国临床药理学杂志,2018,34(5):518-520,527,4.基金项目
河南省高等学校青年骨干教师资助计划基金资助项目(2014GGJS-187) （2014GGJS-187）
